Experts Explain: Viruses, their variants, and vaccines
Over the past week, significant new research has been published on the variants of the novel coronavirus that have emerg...
South Africa has asked the Serum Institute of India to take back the one million COVID-19vaccine doses the company had sent in early February, The Economic Times reported on Tuesday, a week after the country said it will put on hold use of AstraZeneca’s shot in its vaccination program.Serum Institute of India, which is producing AstraZeneca’s shot, has emerged as a key vaccine supplier. One million doses of the COVID-19 vaccine landed in South Africa last week and another 500,000 were due to arrive in the next few weeks.The company did not immediately respond to a Reuters request for comment.South Africa’s health minister has said the government may sell doses of AstraZeneca’s vaccine, after the country paused its roll-out following a small clinical trial that showed it offered minimal protection against mild to moderate illness from the 501Y.V2 coronavirus variant dominant in the country.AstraZeneca has said its vaccine appeared to offer only limited protection against mild disease caused by the South African variant, based on data from a study by South Africa’s University of the Witwatersr and and Oxford University.
This notice has been removed
The content is no longer available
South Africa has asked the Serum Institute of India to take back the one million COVID-19vaccine doses the company had sent in early February, The Economic Times reported on Tuesday, a week after the country said it will put on hold use of AstraZeneca’s shot in its vaccination program.Serum Institute of India, which is producing AstraZeneca’s shot, has emerged as a key vaccine supplier. One million doses of the COVID-19 vaccine landed in South Africa last week and another 500,000 were due to arrive in the next few weeks.The company did not immediately respond to a Reuters request for comment.South Africa’s health minister has said the government may sell doses of AstraZeneca’s vaccine, after the country paused its roll-out following a small clinical trial that showed it offered minimal protection against mild to moderate illness from the 501Y.V2 coronavirus variant dominant in the country.AstraZeneca has said its vaccine appeared to offer only limited protection against mild disease caused by the South African variant, based on data from a study by South Africa’s University of the Witwatersr and and Oxford University.
No results found
Try a different search term
Something went wrong
No notices yet
No notices match these filters
Couldn't load notices
You're all caught up 🎉
Sign in to continue to Global Noticeboard
Enter your email to receive a reset link
Create a new password for your account
You are marking this Notice are inappropriate, and you belive it infringes on the Global Noticeboard Community Guidelines (link). Is this so?
Create 3 Noticeboards to earn this Silver level Community Champion Badge.
View all badges that you can earnPlease tell us why you are reporting this content.
Discussion (0)
No comments yet